AYTU BIOPHARMA, INC Cash and Cash Equivalents
AYTU BIOPHARMA, INC (AYTU) had Cash and Cash Equivalents of $26.31 million as of 2026-06-30, per its 10-K filed 2026-09-22.
Financial Statements › Balance Sheet › Assets › Assets, Current
us-gaap:CashAndCashEquivalentsAtCarryingValue · last filed 2026-09-22
- 2026-06-30: Cash and Cash Equivalents, at Carrying Value $26.31M.
- 2026-03-31: Cash and Cash Equivalents, at Carrying Value $26.71M.
- 2025-12-31: Cash and Cash Equivalents, at Carrying Value $30.02M.
- 2025-09-30: Cash and Cash Equivalents, at Carrying Value $32.63M.
| Period end | Cash and Cash Equivalents, at Carrying Value | Cash and Cash Equivalents, at Carrying Value as first filed |
|---|---|---|
| 2026-06-30 | $26.31M 10-K · filed 2026-09-22 | |
| 2026-03-31 | $26.71M 10-Q · filed 2026-05-13 | |
| 2025-12-31 | $30.02M 10-Q · filed 2026-02-03 | |
| 2025-09-30 | $32.63M 10-Q · filed 2025-11-13 | |
| 2025-06-30 | $30.95M 10-K · filed 2026-09-22 | |
| 2025-03-31 | $18.17M 10-Q · filed 2025-05-14 | |
| 2024-12-31 | $20.40M 10-Q · filed 2025-02-12 | |
| 2024-09-30 | $20.11M 10-Q · filed 2024-11-13 | |
| 2024-06-30 | $20.01M 10-K · filed 2025-09-23 | |
| 2024-03-31 | $19.76M 10-Q · filed 2024-05-15 | |
| 2023-12-31 | $19.53M 10-Q · filed 2024-02-14 | |
| 2023-09-30 | $19.96M 10-Q · filed 2023-11-14 | |
| 2023-06-30 | $22.98M 10-K · filed 2024-09-26 | |
| 2023-03-31 | $19.18M 10-Q · filed 2023-05-11 | |
| 2022-12-31 | $19.50M 10-Q · filed 2023-02-21 | |
| 2022-09-30 | $23.81M 10-Q/A · filed 2023-02-21 | |
| 2022-06-30 | $19.36M 10-K · filed 2023-10-12 | |
| 2022-03-31 | $27.61M 10-Q · filed 2022-05-16 | |
| 2021-12-31 | $35.28M 10-Q · filed 2022-02-14 | |
| 2021-09-30 | $40.31M 10-Q/A · filed 2023-02-21 | |
| 2021-06-30 | $49.65M 10-K · filed 2022-09-27 | |
| 2021-03-31 | $46.54M 10-Q · filed 2022-05-16 | $46.54M 10-Q · filed 2021-05-17 |
| 2020-12-31 | $62.03M 10-Q · filed 2022-02-14 | $62.03M 10-Q · filed 2021-02-11 |
| 2020-09-30 | $37.91M 10-Q · filed 2021-11-15 | $37.91M 10-Q · filed 2020-11-12 |
| 2020-06-30 | $48.08M 10-K · filed 2021-09-28 | $48.08M 10-K · filed 2020-10-06 |
| 2020-03-31 | $62.26M 10-Q · filed 2020-05-15 | |
| 2019-12-31 | $5.26M 10-Q · filed 2020-02-14 | |
| 2019-09-30 | $7.01M 10-Q · filed 2019-11-14 | |
| 2019-06-30 | $11.04M 10-K · filed 2020-10-06 | |
| 2019-03-31 | $14.65M 10-Q · filed 2019-05-14 | |
| 2018-12-31 | $17.80M 10-Q · filed 2019-05-14 | |
| 2018-09-30 | $3.96M 10-Q · filed 2018-11-07 | |
| 2018-06-30 | $7.01M 10-K · filed 2019-09-26 | |
| 2018-03-31 | $12.01M 10-Q · filed 2018-05-14 | |
| 2017-12-31 | $3.91M 10-Q · filed 2018-02-08 | |
| 2017-09-30 | $7.02M 10-Q · filed 2017-11-09 | |
| 2017-06-30 | $802.33K 10-K · filed 2018-09-06 | |
| 2017-03-31 | $3.47M 10-Q · filed 2017-05-11 | |
| 2016-12-31 | $5.23M 10-Q · filed 2017-02-09 | |
| 2016-09-30 | $2.75M 10-Q · filed 2016-11-07 | |
| 2016-06-30 | $8.05M 10-K · filed 2017-08-31 | |
| 2016-03-31 | $8.67M 10-Q · filed 2016-05-11 | |
| 2015-12-31 | $10.96M 10-Q · filed 2017-02-09 | |
| 2015-09-30 | $10.07M 10-Q · filed 2016-11-07 | |
| 2015-06-30 | $7.35M 10-Q · filed 2017-02-09 | |
| 2015-03-31 | $1.49M 10-Q · filed 2016-05-11 | |
| 2014-12-31 | $160.91K 10-Q · filed 2016-02-11 | |
| 2014-09-30 | $1.05M 10-Q · filed 2015-11-06 | |
| 2014-06-30 | $2.64M 10-K · filed 2016-09-01 | |
| 2014-03-31 | $4.12M 10-Q · filed 2015-05-19 | |
| 2013-06-30 | $2.91M 10-K · filed 2015-09-28 | $2.91M 10-Q · filed 2015-05-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NextCure, Inc. (NXTC) | United States | $0.024B | -0.15 |
| TherapeuticsMD, Inc. (TXMD) | United States | $0.024B | -117.87 |
| ARTELO BIOSCIENCES, INC. (ARTL) | United States | $0.023B | |
| KYNTRA BIO, INC. (KYNB) | United States | $0.028B | 0.17 |
| Transcode Therapeutics, Inc. (RNAZ) | United States | $0.029B | -0.12 |
| Cocrystal Pharma, Inc. (COCP) | United States | $0.022B | |
| Hepion Pharmaceuticals, Inc. (HEPA) | United States | $0.029B | -0.62 |
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| IGC Pharma, Inc. (IGC) | United States | $0.029B | -5.98 |
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |